2018年
Resistance to molecularly targeted therapy in non-small-cell lung cancer
Respiratory Investigation
- ,
- ,
- 巻
- 57
- 号
- 1
- 開始ページ
- 20
- 終了ページ
- 26
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1016/j.resinv.2018.09.001
The discovery of oncogenic driver gene mutations, including epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion, ROS proto-oncogene 1 (ROS1) fusion, and ret proto-oncogene (RET) fusion, has led to the development of molecularly targeted therapy for non-small-cell lung cancer (NSCLC). This therapy has changed the standard of care for NSCLC. Despite the dramatic response to molecularly targeted therapy, almost all patients ultimately develop resistance to the drugs. To understand the mechanisms of resistance to molecularly targeted agents, it is essential to understand the molecular pathways of NSCLC. Here, we review the mechanisms of resistance to molecularly targeted therapy and discuss strategies to overcome drug resistance.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.resinv.2018.09.001
- ORCIDのPut Code : 51840744
- PubMed ID : 30293943
- SCOPUS ID : 85054157259